Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Clinical trial NCT05083364 · COMPLETED

Trial details

NCT number: NCT05083364
Sponsor: Arrowhead Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

C3 Glomerulopathy IgA Nephropathy

Start date: 2022-02-01
Primary completion: 2025-09-10
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.